Skip to main content
Premium Trial:

Request an Annual Quote

TDD to Use Inform Genomics' Technology in Drug Development Services

NEW YORK (GenomeWeb) – Inform Genomics and Translational Drug Development today announced a collaboration in which TDD will offer Inform's technology and analytic capabilities as part of its drug development services for biopharmaceutical firms. Financial and other terms of the deal were not disclosed.

According to Inform's website, its technology predicts clinical outcomes that physicians and patients can use to make individualized medical decisions. Based on big data storage and memory, and cloud computing technologies, Inform's analytics discover gene-SNP interactions for predicting clinical outcomes. Its lead development program is in support of cancer care, and the company is currently developing two products called OnPart and HSCT/Mucositis to predict a patient's risk for developing common chemotherapy-related side effects.

TDD's "focus on precision oncology solutions, coupled with Inform Genomics' ability to understand individual patient risk for side effects, can give a more complete vision of personalized medicine that has the opportunity to significantly improve patient care," TDD President and CEO Stephen Gately said in a statement.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.